Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma In vitro and In vivo

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5263-5269

  Ganslmayer, Marion ^a   Konturek, Peter ^b   Herold, Christoph ^a   Neurath, Markus F ^a   Zopf, Steffen ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Thueringen Clinic   (Germany)

Author keywords

HCC; Hepatocellular carcinoma; Histonedeacetylase inhibitor; MS 275; SAHA; Trichostatin A

Indexed keywords

ANTINEOPLASTIC AGENT; ENTINOSTAT; FK 901228; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; RATS, INBRED BUF;

EID: 84872579904     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y and Tang W: The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011. Liver Int 32: 1053-1063, 2012.
2. Herold C, Ganslmayer M, Ocker M, Hermann M, Hahn EG and Schuppan D: The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36: 233-240, 2002.
3. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A and Montalto G: Targeted therapy for hepatocellular carcinoma: Novel agents on the horizon. Oncotarget 3: 236-260, 2012.
4. Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-54689, 2009.
5. Atadja PW: HDAC inhibitors and cancer therapy. Prog Drug Res 67: 175-195, 2011.
6. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-35, 2006.
7. Schrump DS: Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 15: 3947-3957, 2009.
8. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, Kenner L and Seiser C: Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 10: 406-412, 2011.
9. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S and Sparano JA: Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117: 336-342, 2011.
10. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J and Sausville EA: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 3912-3922, 2005.
11. Inoue S, Harper N, Walewska R, Dyer MJ, Cohen GM: Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 8: 3088-3097, 2009.
12. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356, 2007.
13. Bracker TU, Sommer A, Fichtner I, Faus H, Haendler B and Hess-Stumpp H: Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 35: 909-920, 2009.
14. Hess-Stumpp H, Bracker TU, Henderson D, Politz O: MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int J Biochem Cell Biol 39: 1388-1405, 2008.
15. Panagiotis A, Konstantinopoulos GP and Vandoros G. FK 228: A HDAC inhibitor with pleiotrobic antitumora activities. Cancer Chemother Pharmacol 58: 711-715, 2008.
16. Clark JD, Gebhart GF, Gonder JC, Keeling ME and Kohn DF: Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J 38: 41-48, 1997.
17. Aldana-Masangkay GI, Sakamoto KM: The role of HDAC6 in cancer. J Biomed Biotechnol 2011: 875-885, 2011.
18. Mandana N, Perez G, Ngo L, Marks OA: Selective inhibition od HDAC 6 induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci 107: 20003-20008, 2011.
19. Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY, Park CG, Kang J: Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25: 1677-1681, 2011.